MEDVi vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Willow scores higher on our rubric, 7.5/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit MEDVi - $179 first month, then $299/mo →or find your match

Willow beats MEDVi overall, scoring 7.5/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Willow is from $299/mo. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program. Choose Willow for users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

A side-by-side look at MEDVi and Willow to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MEDVi

#46 of 54

5.7/10

MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.

Visit MEDVi

Higher Rated

Willow

#20 of 54

7.5/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only, Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	MEDVi	Willow
Why each one	Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.	One of the few compounded-only platforms offering both injectable and daily oral semaglutide tablets, useful for users who want a non-injectable option without leaving the GLP-1 compounded category.
Our Score	5.7/10	7.5/10
Headline Price	$179 first month, then $299/mo	from $299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Users who want both oral and injectable compounded options in one telehealth program	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Watch out for	FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication	Compounded-only, no brand-name Wegovy or Zepbound through the platform
Ranking	#46	#20
Get started	Visit MEDVi	Visit Willow

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping

Cons

−FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
−Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
−The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
−Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide, one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only, no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses, starting dose is $399/mo
−Cash-pay only, no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024, less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out MEDVi with a score of 7.5/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Willow is from $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility.